From owner-sci-resources@net.bio.net Sun May 02 23:00:00 1993 Path: biosci!agate!usenet.ins.cwru.edu!cleveland.Freenet.Edu!da650 From: da650@cleveland.Freenet.Edu (Keri L. Karnbad) Newsgroups: bionet.sci-resources Subject: reasearch Message-ID: <1s3n80$qfg@usenet.INS.CWRU.Edu> Date: 3 May 93 18:11:12 GMT Organization: Case Western Reserve University, Cleveland, Ohio (USA) Lines: 7 NNTP-Posting-Host: hela.ins.cwru.edu Hello my name is Keri Karnbad, and I am a student at Stockton College in NJ. I am am doing a project for a computer class and I need all the if[D sorry informatiot ioon I can on Biology and or Genetics. I need FTP sights, listservs, or any otheh er places to find information in this area. I am sorry this is so sloppy, this is my first message. my address is STK1694@vax003.stockton.edu From owner-sci-resources@net.bio.net Sun May 02 23:00:00 1993 Path: biosci!agate!howland.reston.ans.net!zaphod.mps.ohio-state.edu!malgudi.oar.net!zeus.franklin.edu!blair From: blair@zeus.franklin.edu (John Blair) Newsgroups: bionet.sci-resources Subject: ftp sites Message-ID: <1993May3.190113.17751@zeus.franklin.edu> Date: 3 May 93 19:01:13 GMT Organization: Franklin University Lines: 27 I need to find an ftp site or sites where I can find a software graphics package to allow the interactive placement of dots and lines for my senior project in computer science (chaotic systems and iterative function theory. I would also like to find any source code I can for graphically generating chaotic and fractal images. All I've found so far is a BASIC program which produces the Mandlebrot set but I'm unable to print out or zoom in on the graph produced. My primary interest is in the equations used in atmospheric modeling. I would appreciate any help anyone can provide me. Please e-mail your replies as I'm posting to several groups I don't subscribe too. Thank you in advance jb address: blair@zeus.franklin.edu From owner-sci-resources@net.bio.net Mon May 03 23:00:00 1993 Path: biosci!NET.BIO.NET!kristoff From: kristoff@NET.BIO.NET (Dave Kristofferson) Newsgroups: bionet.sci-resources Subject: NSF - Summary of new documents on STIS - 2 May 1993 Message-ID: Date: 4 May 93 05:04:15 GMT Sender: kristoff@net.bio.net Distribution: bionet Lines: 134 ** NEW DOCUMENTS ON STIS ** Document Type: EPS Title: NSF Electronic Proposal Submission Project - Frequently Asked Questions File size (bytes): 1396 STIS Filename: epsfaq Document Type: Letter Title: Research in All-Optical Network and Communications File size (bytes): 6433 STIS Filename: lcise930 Title: Research in All-Optical Network and Communications File size (bytes): 6432 STIS Filename: leng9301 Title: Program Announcement-Human Brain Project File size (bytes): 38085 STIS Filename: lmps9301 Document Type: Program Guideline Title: NSF 93-46 - EHR Activities in Science, Engineering, and Mathematics for Persons with Disabilities File size (bytes): 77718 STIS Filename: nsf9346 Title: The US Tropical Ocean Global Atmosphere Program Coupled Ocean-Atmoshpere response Experiment (NSF 93-57) File size (bytes): 10966 STIS Filename: nsf9357 Title: Management of Technological Innovation 1993 Focus on Management of Innovation for Environmentally Conscious Manufacturing File size (bytes): 17344 STIS Filename: nsf9363 Document Type: Recruit Title: Assistant Inspector General for Audit File size (bytes): 6437 STIS Filename: vep9305 Title: Decision Science Administrator (Program Director) File size (bytes): 4514 STIS Filename: vex9317 Title: Physicist (Program Director) File size (bytes): 3499 STIS Filename: vex9318 Document Type: Report Title: OIG Review of NSFNET File size (bytes): 177211 STIS Filename: oig9301 ------------------------------------------------------------------------ ** UPDATES TO EXISTING STIS DOCUMENTS ** Document Type: Phone Book Title: NSF Alphabetical Listing File size (bytes): 90518 STIS Filename: phnalpha Title: NSF Alphabetical Listing File size (bytes): 90518 STIS Filename: phnalpha Title: NSF Organizational Directory File size (bytes): 95397 STIS Filename: phnorg Title: NSF Organizational Directory File size (bytes): 95397 STIS Filename: phnorg Document Type: Program Guideline Title: NSF 93-40 -- Young Scholars File size (bytes): 65991 STIS Filename: nsf9340 Title: NSF 93-54 - Research Fellowship in Marine Biotechnology and the Ocean Sciences File size (bytes): 19000 STIS Filename: nsf9345 ------------------------------------------------------------------------ ** FOR YOUR REFERENCE ** ------------------------------------------------------------------------ HOW TO OBTAIN DOCUMENTS The above files can be retrieved in electronic form using the STIS system. If you don't know how to use STIS, send an E-mail message to stisinfo@nsf.gov (Internet) or stisinfo@NSF (BITNET). You will receive a copy of the STIS flyer via E-mail. If you are already using STIS, you can use the information above to retrieve these files: Documents via E-mail: Send a message to stisserv@nsf.gov (Internet) or stisserv@NSF (BITNET). Use the "STIS Filename" shown above in the "get" command. For example, to retrieve nsf9345, the text of your message should be as follows: get nsf9345 Anonymous FTP: FTP to stis.nsf.gov. Use the "STIS Filename" shown above to retrieve a file. For example, to retrieve nsf9345, you would enter: ftp> get nsf9345 WAIS or Gopher: Do a word search on the filename as shown in the summary. If you want a *printed* copy of a document: Send your name and postal mailing address, and the document title and number to "firstop@nsf.gov" (Internet) or "firstop@nsf" (BITNET). If you have problems with the above procedures: Send a message to "stis@nsf.gov" (Internet) or "stis@NSF" (BITNET). From owner-sci-resources@net.bio.net Thu May 06 23:00:00 1993 Path: biosci!NET.BIO.NET!kristoff From: kristoff@NET.BIO.NET (Dave Kristofferson) Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 22, no. 18, pt. 1, 7 May 1993 Message-ID: Date: 7 May 93 18:11:21 GMT Sender: kristoff@net.bio.net Distribution: bionet Lines: 1506 NOTE: The NIH Guide may be split into more than one mail message to avoid truncation during e-mail distribution. The first message always begins with the RFP/RFA summary sections followed by the appended texts of the full RFP/RFAs. ---------------------------------------------------------------------- $$XID NIHGUIDE 19930507 V22N18 P1O2 ************************************ X-comment: RFAS described: CA-93-021, DK-93-023, CA-93-025, CA-93-026, NR-93- 005, DK-93-007, DK-93-008 NIH GUIDE - Vol. 22, No. 18 - May 7, 1993 $$INDEX BEGIN ******************************************************* NOTICES OF AVAILABILITY (RFPs AND RFAs) $$INDEX R1 ********************************************************** NATIONAL CENTER FOR THE ADVANCEMENT OF PREVENTION (RFP 277-93-1013) Center for Substance Abuse Prevention INDEX: SUBSTANCE ABUSE PREVENTION $$INDEX R2 08/12/93 ************************************************* PREVENTION CLINICAL TRIALS UTILIZING INTERMEDIATE ENDPOINTS AND THEIR MODULATION BY CHEMOPREVENTIVE AGENTS (RFA CA-93-021) National Cancer Institute INDEX: CANCER $$INDEX R3 08/20/93 ************************************************* INTERVENTIONS IN DIABETES AMONG MINORITY POPULATIONS (RFA DK-93-023) National Institute of Diabetes and Digestive and Kidney Diseases National Center for Nursing Research INDEX: DIABETES, DIGESTIVE, KIDNEY DISEASES; NURSING RESEARCH $$INDEX R4 08/24/93 ************************************************* COMMUNITY CLINICAL ONCOLOGY PROGRAM (RFA CA-93-025) National Cancer Institute INDEX: CANCER $$INDEX R5 08/24/93 ************************************************* MINORITY-BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM (RFA CA-93-026) National Cancer Institute INDEX: CANCER $$INDEX R6 09/22/93 ************************************************* SMALL GRANTS PROGRAM FOR NURSING AND BIOLOGY INTERFACE (RFA NR-93-005) National Center for Nursing Research INDEX: NURSING RESEARCH $$INDEX R7 10/19/93 ************************************************* NON-INSULIN DEPENDENT DIABETES PRIMARY PREVENTION TRIAL (RFA DK-93-007) National Institute of Diabetes and Digestive and Kidney Diseases National Institute of Child Health and Human Development Office of Research on Minority Health INDEX: DIABETES, DIGESTIVE, KIDNEY DISEASES; CHILD HEALTH, HUMAN DEVELOPMENT; MINORITY HEALTH $$INDEX R8 10/19/98 ************************************************* NIDDM PRIMARY PREVENTION TRIAL: DATA COORDINATING CENTER (RFA DK-93-008) National Institute of Diabetes and Digestive and Kidney Diseases INDEX: DIABETES, DIGESTIVE, KIDNEY DISEASES This publication is also available electronically to institutions via BITNET or INTERNET. Alternative access is through the NIH Grant Line using a personal computer (data line 301/402-2221). Contact Dr. John James at 301/594-7270 for details, or send an E-mail message to ZNS@NIHCU. $$INDEX END ********************************************************* NOTICES OF AVAILABILITY (RFPs AND RFAs) $$R1 BEGIN 277-93-1013 ********************************************** NATIONAL CENTER FOR THE ADVANCEMENT OF PREVENTION NIH Guide, Volume 22, Number 18, May 7, 1993 RFP AVAILABLE: 277-93-1013 P.T. 34; K.W. 0404009, 0745027 Center for Substance Abuse Prevention The Center for Substance Abuse Prevention (CSAP) proposes to award a three year cost-reimbursement, level-of-effort type contract to establish a National Center for the Advancement of Prevention, which will assist CSAP in achieving its mission by developing and providing knowledge synthesis and transfer mechanisms, providing proactive technical assistance to States and through the States to the field, and by developing and providing state-of-the-art evaluation methodologies and tools. The Center is expected to be composed of a core, which would handle coordination and administrative responsibilities, and three components, one for each of the areas previously stated. The Center will require a group of highly skilled experts in the areas of substance abuse prevention services, evaluation and research, cost/benefit analysis, needs assessment, instrument development, statistics, computer programming, database and communications systems, other social sciences and training. These experts will support CSAP's mission by providing state-of-the-art knowledge to enhance the effectiveness of substance abuse prevention programs in the State and in communities. Additionally, three options are proposed within the contract. Option I concerns expanding and elaborating effective prevention strategy models, guidelines, and protocols. Option II concerns the development of a prototype for a possible regional system for dissemination, technical assistance, and training and Option III concerns performing developmental work for the future national prevention database and potential community based surveillance systems to monitor alcohol and other drug abuse incidence, prevalence, and related sequelae. It is estimated that 36 months will be required for this project. However, two separate one-year extension options are also included. INQUIRIES This is an announcement for an anticipated Request For Proposal (RFP). RFP No. 277-93-1013 will be available approximately May 14, 1993, with a closing date tentatively set for June 17, 1993. Requests for the RFP along with two self-addressed labels must be submitted in writing to: Catherine Kellington Contract Management Branch Center for Substance Abuse Prevention 5600 Fishers Lane Rockwall II Building, Room 670 Rockville, MD 20857 $$R1 END ************************************************************ $$R2 BEGIN CA-93-021 FULL-TEXT ************************************** PREVENTION CLINICAL TRIALS UTILIZING INTERMEDIATE ENDPOINTS AND THEIR MODULATION BY CHEMOPREVENTIVE AGENTS NIH Guide, Volume 22, Number 18, May 7, 1993 RFA AVAILABLE: CA-93-021 P.T. 34; K.W. 0715035, 0755015, 0710095, 0740018 National Cancer Institute Letter of Intent Receipt Date: May 28, 1993 Application Receipt Date: August 12, 1993 THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION. POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES, BELOW. PURPOSE The Division of Cancer Prevention and Control (DCPC), National Cancer Institute (NCI), invites applications for cooperative agreements to support clinical trials that are directed toward examining the role of various chemopreventive agents and/or diet in the prevention of cancer. This is a follow-up to earlier RFAs which had requested grants, and then later cooperative agreement proposals in this area. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Prevention Clinical Trials Utilizing Intermediate Endpoints and Their Modulation by Chemopreventive Agents, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00476-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal Government. Applications from minority individuals and women are encouraged. MECHANISM OF SUPPORT Applicants funded under this RFA will be supported through the cooperative agreement (U10) mechanism for which substantial NIH programmatic staff involvement is expected. An assistance relationship will exist between NCI and the awardees to accomplish the purpose of the activity. The recipients will have primary responsibility for the development and performance of the activity. However, there will be government involvement with regard to (1) assistance securing an Investigational New Drug (IND) approval from the Food and Drug Administration (FDA), (2) monitoring of safety and toxicity and, (3) coordination and assistance in obtaining the chemopreventive agent, (4) quality assurance with regard to the clinical chemistry aspects of the study. Responsibility for planning, direction, and execution of the proposed project will be solely that of the applicant. The total project period for applications submitted in response to the present RFA may not exceed five years. This RFA will be issued annually for three years. Future unsolicited continuation applications will compete with all other investigator-initiated applications and be reviewed by a study section in the Division of Research Grants. However, if the NCI determines that there is sufficient continuing program need, NCI may invite all funded recipients to submit competing continuation applications. Competing continuation applications will not compete with new applications for funding. FUNDS AVAILABLE Approximately $1.5 million in total costs for the first year will be committed to fund applications submitted in response to this RFA. The project period may not exceed five years. It is anticipated that three to five awards will be funded. This level of support is dependent on the receipt of sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NCI, awards pursuant to this RFA are also contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES The major objective of this solicitation is to encourage cancer chemoprevention clinical trials that utilize biochemical and/or biological markers to identify populations at risk and/or to provide intermediate endpoints that may predict later reduction in cancer incidence rates. These studies may be developed in phases, including a pilot phase, which could later proceed to a full scale intervention. The main emphasis should be on small, efficient studies aimed at improving future research designs of chemoprevention trials, providing biologic understanding of what is happening in the trials, or providing better, more quantitative and more efficient endpoints for these trials. After successful completion of the pilot phase (i.e., demonstrated modulation of marker endpoints by the intervention), subsequent studies could include a definitive clinical trial monitoring the test system, a cancer incidence or mortality endpoint, and a designated agent. Investigators may apply at this time for the pilot phase, or submit an application for both the pilot and definitive trial studies. However, if the application is for the pilot phase only, the proposed study must describe its relevance to a clinical application and utilize a chemopreventive agent, marker test system, and study population that could later be the subject of a full scale, double-blind, randomized, risk reduction clinical trial. Intermediate marker trials of breast cancer chemoprevention are especially encouraged. STUDY POPULATION SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES For projects involving clinical research, NIH requires applicants give special attention to the inclusion of women and minorities in study populations. If women or minorities are not included in the study populations for clinical studies, a specific justification for this exclusion must be provided. Applications without such documentation will not be accepted for review. LETTER OF INTENT Prospective applicants are asked to submit, by May 28, 1993, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NCI staff to estimate the potential review workload and to avoid possible conflict of interest in the review. The letter of intent is to be sent to Dr. Marjorie Perloff at the address listed under INQUIRIES. APPLICATION PROCEDURES The receipt date for applications is August 12, 1993. The research grant application form PHS 398 (rev - 9/91) is to be used in applying for these cooperative agreements. These forms are available at most institutional offices of sponsored research; from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, Westwood Building, 5333, Room 449 Bethesda, MD 20892, telephone 301/594-7248; and from the NCI Program Director named below. The RFA label available in the application form PHS 398 must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the title of the application, "Prevention Clinical Trials Utilizing Intermediate Endpoints and Their Modulation by Chemopreventive Agents", and the RFA number, CA-93-021, must be typed in block 2a of the face page of the application form. Submit a signed, typewritten original of the application, including the Checklist, and three signed, exact, clear and single-sided photocopies, in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At time of submission, two additional copies of the application must also be sent to: Ms. Toby Friedberg, Referral Officer Division of Extramural Activities National Cancer Institute Executive Plaza North, Room 636 6130 Executive Boulevard Bethesda, MD 20892 REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed (initially) by the Division of Research Grants (DRG) for completeness. Incomplete applications will be returned to the applicant without further consideration. Evaluation for responsiveness to the RFA is an NCI program staff function. Applications will be judged to determine if they meet the goals and objectives of the program as described in the RFA. Applications that are judged non-responsive will be returned, but may be submitted as investigator initiated grants at the next receipt date. Those applications judged to be both competitive and responsive will be further evaluated, using the review criteria shown below, for scientific and technical merit by an appropriate peer review group convened by the Division of Extramural Activities, NCI. The second level of review by the National Cancer Advisory Board considers the special needs of the Institute and the priorities of the National Cancer Program. INQUIRIES Written and telephone requests for the RFA and the opportunity to clarify any issues or questions from potential applicants are welcome. Direct requests for the RFA, inquiries regarding programmatic issues, and address the letter of intent to: Marjorie Perloff, M.D. Chemoprevention Branch National Cancer Institute Executive Plaza North, Suite 201 Bethesda, MD 20892 Telephone: (301) 496-8563 Direct inquiries regarding fiscal matters to: Ms. Eileen Natoli Grants Administration Branch National Cancer Institute Executive Plaza South, Suite 243 Bethesda, MD 20892 Telephone: (301) 496-7800 Ext. 56 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance Number 93.399, Cancer Control.Awards will be made under the authority of the Public Health Service Act, Title IV, Section 301 (Public Law 78-410,; 42 U.S.C. 241, and Section 412, as amended by Public Law 99-158, 42 U.S.C. 258a-1); and administered under PHS grant policies and Federal regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$R2 END ************************************************************ $$R3 BEGIN DK-93-023 FULL-TEXT ************************************** INTERVENTIONS IN DIABETES AMONG MINORITY POPULATIONS NIH Guide, Volume 22, Number 18, May 7, 1993 RFA AVAILABLE: DK-93-023 P.T. 34, FF; K.W. 0715075, 0785035, 0745027 National Institute of Diabetes and Digestive and Kidney Diseases National Center for Nursing Research Letter of Intent Receipt Date: July 20, 1993 Application Receipt Date: August 20, 1993 THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION. POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES, BELOW. PURPOSE This RFA invites new and experienced investigators to submit clinical research applications designed to develop and validate intervention approaches for the amelioration or prevention of diabetes mellitus and/or its complications among minority populations, including African, Asian, and Hispanic Americans, Native Hawaiians, and Pacific Islanders. This RFA is a follow-up to the RFA DK-91-09 "Research Planning Grant: Diabetes in Minority Populations." However, respondents to this RFA are not restricted to those having previously received a planning grant under the prior RFA. Applications are encouraged from any interested investigators regardless of their prior record of grant support. Although this RFA is designed to develop and validate interventions for preventing diabetes mellitus and/or its complications, the National Institute of Diabetes and Digestive Kidney Diseases is announcing another RFA (DK-93-007) specifically for clinical centers to design and implement a full-scale, multi-center clinical trial to evaluate the efficacy of interventions designed to delay or prevent onset of non- insulin dependent diabetes mellitus in individuals at increased risk for the disease. The present RFA focuses on the specific minority populations as indicated above. An earlier RFA (DK-92- 17) was designed for studies with Native Americans and Alaskan Natives. While studies involving these populations are not responsive to the present RFA, investigators interested in working with these groups are advised to submit applications through the normal NIH investigator-initiated review process. The NIDDK and the National Center for Nursing Research seek to encourage research on all minority populations. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Intervention Studies in Diabetes Among Minority Populations, is specifically targeted at diabetes mellitus and its complications as a major public health problem. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone: 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign non-profit and for-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of state and local governments and eligible agencies of the Federal government. Teams of applicants are encouraged which could include universities, public health departments, voluntary organizations, and health clinics. Among a team of applicants, one institution must be proposed as the lead organization to serve as the Grantee Institution and assume responsibility for the fiscal and programmatic conduct of the project. Other members of the team should be proposed based on individual consortium agreements (subcontracts) with those organizations. The grantee organization and any proposed consortium must have the staff and facilities required for the proposed program. Applications from minority individuals and women are encouraged. MECHANISM OF SUPPORT Support of this program will be through the NIH research project grant (R01) award. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. Awards will be administered under PHS grants policy as stated in the PHS Grants Policy Statement. This RFA is a one-time solicitation. Future unsolicited competing continuation applications will compete with all investigator-initiated applications and be reviewed according to the customary peer review procedures. The total requested project period for applications submitted in response to this RFA may not exceed five years. A maximum of three years can be requested for foreign awards. The earliest possible award date will be April 1, 1994. Applicants must limit their request to not more than $160,000 direct costs for the initial budget period. The average size of a grant is expected to be approximately $190,000 total costs. FUNDS AVAILABLE For fiscal year 1994, $2.2 million will be committed to fund applications submitted in response to this RFA. The NIDDK and the NCNR plan to support approximately 10 to 12 applications submitted in response to this solicitation. However, this funding level is dependent upon the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NIDDK and the NCNR, the award of grants pursuant to this RFA is contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES Diabetes mellitus and its complications are major public health problems in the United States today. The National Institutes of Health has encouraged research into the cause, cure and prevention of diabetes and its related endocrine and metabolic disorders. The overall objective of this RFA is to stimulate original and innovative studies directed at the elucidation of practical methods for the reduction of the public health burden of diabetes in African, Asian and Hispanic Americans, Pacific Islanders, and Native Hawaiians. Examples of research topics relevant to this solicitation are listed below, they should not be construed as required or limiting. Responsive applications to this RFA include: o Development and validation of efficacious strategies for changing health behaviors of people with or at high risk for diabetes with specific emphasis on high risk populations. o Development and validation of interventions designed to prevent NIDDK or its major risk factors, such as obesity, on a community wide basis for high risk populations. o Development and validation of interventions designed to prevent NIDDM in targeted high risk subgroups (e.g., documented impaired glucose tolerance, history of gestational diabetes, obese children or young adults,) within the population. o Development and validation of interventions designed to improve the care of minority patients with NIDDM. o Development and validation of interventions designed to reduce or prevent the long-term complications of diabetes among minority populations. o Clinical studies of the physiologic effects of alternative pharmacologic and non-pharmacologic interventions for the treatment of NIDDM in minority populations. SPECIAL REQUIREMENTS The research team, composed of the Principal Investigator and/or collaborators, must include individual(s) who are experienced in clinical research. Involvement of individuals who have demonstrated experience working with or delivering health services to minority populations is highly desirable. The application should include a succinct discussion of previous relevant investigational and health care activities. Letters of collaboration should be included for all proposed consultants/collaborators. The applicant must demonstrate that the research team has an understanding of and sensitivity to the target population. Where specific language or cultural barriers are important, the applicant must provide a plan for addressing these barriers. STUDY POPULATIONS SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES For projects involving clinical research, NIH requires applicants to give special attention to the inclusion of women and minorities in study populations. If women or minorities are not included in the study populations for clinical studies, a specific justification for this exclusion must be provided. Applications without such documentation will not be accepted for review. LETTER OF INTENT Prospective applicants are asked to submit, by July 20, 1993, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. If allows NIDDK staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to: Chief, Review Branch National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 605 Bethesda, MD 20892 Telephone: (301) 594-7515 APPLICATION PROCEDURES Applications are to be submitted using form PHS-398 (rev. 9/91), available in the office of sponsored research of most academic or research institutions and from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone 301-594-7248. The RFA label available in the PHS 398 application form must be affixed to the bottom of the face page. Detailed instructions on submission procedures are described in the RFA. REVIEW CONSIDERATIONS Applications that are complete and responsive to the RFA will be evaluated by an appropriate peer review group convened by the NIDDK in accordance with the usual NIH peer review procedures. Following review, the applications will be given a secondary review by the NIDDK Advisory Council unless not recommended for further consideration by the initial review group. Applications that are incomplete or unresponsive to the RFA will be returned to the applicant or held until the next regular receipt date and reviewed by the Division of Research Grants. INQUIRES Written and telephone inquiries concerning this RFA are encouraged. Requests for the RFA and inquiries regarding programmatic issues may be directed to: Charles A. Wells, Ph.D. Division of Diabetes, Endocrinology, and Metabolic Diseases National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 622 Bethesda, MD 20892 Telephone: (301) 594-7505 June R. Lunney, Ph.D., R.N. Acute and Chronic Illness Branch National Center for Nursing Research Westwood Building, Room 754 Bethesda, MD 20892 Telephone: (301) 594-7397 Inquiries regarding fiscal matters may be directed to: Ms. Betty Bailey Division of Extramural Activities National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 649 Bethesda, MD 20892 Telephone: (301) 594-7543 Sally A. Nichols Grant Management Officer National Center for Nursing Research Westwood Building, Room 748 Bethesda, MD 20892 Telephone: (301) 594-7498 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No 93.848. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$R3 END ************************************************************ $$R4 BEGIN CA-93-025 FULL-TEXT ************************************** COMMUNITY CLINICAL ONCOLOGY PROGRAM NIH Guide, Volume 22, Number 18, May 7, 1993 RFA AVAILABLE: CA-93-025 P.T. 34; K.W. 0715035, 0755015, 0745027, 0403004 National Cancer Institute Letter of Intent Receipt Date: June 25, 1993 Application Receipt Date: August 24, 1993 THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION. POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES, BELOW. PURPOSE The Division of Cancer Prevention and Control (DCPC), National Cancer Institute (NCI), invites applications from domestic institutions for cooperative agreements to the Community Clinical Oncology Program (CCOP). New community and research base applicants and currently funded programs are invited to respond to this RFA. This issuance of the CCOP RFA seeks to build on the strength and demonstrated success of the CCOP over the past ten years by continuing the program to support community participation in cancer treatment and cancer prevention and control clinical trials through research bases (clinical cooperative groups and cancer centers supported by NCI) and utilizing the CCOP network for conducting NCI-assisted cancer prevention and control research. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Community Clinical Oncology Program, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001- 00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS New applicants and currently funded programs are eligible as described below. Two types of grantees are eligible to apply: community programs and research bases. Community applicants may be a hospital, a clinic, a group of practicing physicians, a health maintenance organization (HMO) or a consortium of these. Community programs (CCOPs) will be required to enter patients onto NCI-approved treatment and cancer prevention and control clinical trials through the research base(s) with which each CCOP is affiliated. Research base applicants must be either an NCI-funded clinical trials cooperative group or cancer center. Research bases will be required to provide clinical research treatment and cancer prevention and control protocols, monitor the quality research and follow CCOP accrual. MECHANISM OF SUPPORT Support of this program will be through the Cooperative Agreement (U10) an assistance mechanism in which substantial NCI programmatic involvement with the recipient during performance of the planned activity is anticipated, to assist awardees in the planning, direction, and execution of the proposed project. The total project period for applications submitted in response to this RFA may not exceed three years for new applicants and five years for applicants currently supported under this program. Currently supported applicants will be funded for three, four, or five years depending upon priority score/percentile, review committee recommendations, and programmatic considerations. FUNDS AVAILABLE It is anticipated that up to $4.2 million in total costs per year for five years will be committed to specifically fund applications which are submitted in response to this RFA. Of the total, approximately $1.8 million will be committed to research bases and approximately $2.4 million to CCOPs. It is anticipated that up to three research base awards and up to 15 CCOP awards will be made. This level of support is dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of NCI, awards pursuant to this RFA are contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES Background Over 80 percent of patients with cancer are treated in the community. The CCOP was initiated in 1983 to bring the benefits of clinical research to cancer patients in their own communities by providing support for physicians to enter patients onto treatment research protocols. The second RFA, issued in 1986, expanded the focus to include cancer prevention and control research. In 1992, there were 51 programs in 27 states involving over 300 hospitals and over 2,800 physicians. Approximately 5,000 patients were entered onto treatment trials and 4,000 subjects per year on cancer prevention and control studies. Cancer prevention and control research in the CCOPs is aimed at reducing cancer incidence, morbidity, and mortality through the identification, testing, and evaluation of interventions in controlled clinical trials. The 80 protocols activated to date cover the full spectrum of cancer prevention and control research, including chemoprevention and marker studies for future prevention interventions, smoking cessation studies, screening and early detection, and pain control and other symptom management interventions. Goals and Scope The CCOP initiative is designed to bring the advantages of state-of-the-art treatment and cancer prevention and control research to individuals in their own communities by having practicing physicians and their patients/subjects participate in NCI-approved treatment and cancer prevention and control clinical trials. The CCOP also provides a mechanism to increase the involvement of primary health care providers and other health care specialists in treatment and cancer prevention and control research and provides an opportunity for education and exchange of information on new technologies. STUDY POPULATIONS SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES For projects involving clinical research, NIH requires applicants to give special attention to the inclusion of women and minorities in study populations. If women or minorities are not included in the study populations for clinical studies, a specific justification for this exclusion must be provided. Applications without such documentation will not be accepted for review. LETTER OF INTENT Prospective applicants are asked to submit, by June 25, 1993, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NCI staff to estimate the potential review workload and to avoid possible conflict of interest in the review. Letters of intent are to be sent to Dr. Leslie G. Ford at the address listed under INQUIRIES. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for cooperative agreements. These forms are available at most institutional offices of sponsored research; from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone 301/594-7248; and from the NCI program official listed under INQUIRIES. A suggested format will be sent to all applicants requesting the RFA or submitting a letter of intent. Applicants are strongly encouraged to use the suggested format instructions in completing the PHS 398. Submit a signed, typewritten original of the application, including the Checklist, and three signed, exact, clear, and single-sided photocopies, in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, two additional copies of the application must also be sent to: Ms. Toby Friedberg Review Logistics Branch National Cancer Institute Executive Plaza North, Room 636 6130 Executive Boulevard Rockville, MD 20852 Applications must be received by August 24, 1993. If an application is received after that date, it will be returned to the applicant. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed by Division of Research Grants staff or completeness and NCI staff for responsiveness. Incomplete or non-responsive applications will be returned to the applicant without further consideration. If the number of applications is large compared to the number of awards to be made, applications may receive a preliminary scientific peer review (triage) to determine their relative competitiveness. The NCI will withdraw from further competition those applications judged to be non-competitive for award and notify the applicant Principal Investigator and institutional official. Those applications judged to be competitive will undergo further scientific merit review in accordance with the criteria stated below for scientific/technical merit by an appropriate peer review group convened by the Division of Extramural Activities, NCI. The second level of review will be provided by the National Cancer Advisory Board. Review Criteria Review Criteria for CCOP applicants include the ability to accrue a minimum of 50 credits per year to cancer prevention and control clinical trials and at least 50 credits to cancer treatment clinical trials. Review criteria for Research Bases include the ability to design appropriate treatment and/or prevention and control clinical trials. For both CCOPs and Research Bases the qualifications and experience of personnel and the stability and past performances of the functional unit applying will also be considered. The review group will critically examine submitted budgets and recommend an appropriate budget and period of support. AWARD CRITERIA The anticipated date of award is June 1, 1994. NCI program staff will take into account demographic and geographic distribution of applicants in the final funding selection process to assure inclusion of minority and undeserved populations. Multiple CCOP applicants for funding who are competing for the same patient population will be considered, but all may not be awarded unless warranted by the population density. INQUIRIES Written and telephone requests for the RFA, inquiries concerning the objectives and scope of this RFA, or whether or not specific proposed research are responsive are encouraged and may be directed to: Leslie G. Ford, M.D. Community Oncology and Rehabilitation Branch National Cancer Institute Executive Plaza North, Room 300-D Bethesda, MD 20892 Telephone: (301) 496-8541 Direct inquiries regarding fiscal matters to: Ms. Crystal Elliott Grants Administration Branch National Cancer Institute Executive Plaza South, Room 243 Bethesda, MD 20892 Telephone: (301) 496-7800, Ext. 19 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 13.399, Cancer Control. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410 as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$R4 END ************************************************************ $$R5 BEGIN CA-93-026 FULL-TEXT ************************************** MINORITY-BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM NIH Guide, Volume 22, Number 18, May 7, 1993 RFA AVAILABLE: CA-93-026 P.T. 34, FF; K.W. 0715035, 0755015, 0745027, 0403004 National Cancer Institute Letter of Intent Receipt Date: June 25, 1993 Application Receipt Date: August 24, 1993 THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION. POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES BELOW. PURPOSE The Division of Cancer Prevention and Control (DCPC), National Cancer Institute (NCI), is interested in continuing the established cancer control effort which involves practicing oncologists who serve large minority populations in the NCI clinical trials program. DCPC invites applications from domestic institutions with greater than 50 percent of new cancer patients from minority populations for cooperative agreements in response to this Minority-Based Community Clinical Oncology Program (MBCCOP) RFA. This issuance of the MBCCOP RFA seeks to build on the strength and demonstrated success of the MBCCOP over the past three years by: (1) continuing the program as a vehicle for supporting community participation in treatment and cancer prevention and control clinical trials through research bases (clinical cooperative groups and cancer centers supported by NCI); (2) expanding and strengthening the cancer prevention and control research effort; (3) utilizing the MBCCOP network for conducting NCI-assisted cancer prevention and control research; and (4) evaluating on a continuing basis MBCCOP performance and its impact in the community. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Minority - based Community Clinical Oncology Program, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS New applicants and currently funded programs are eligible as described below. Community applicants may be a hospital, a clinic, a group of practicing physicians, a health maintenance organization (HMO) or a consortium of these. Applicants must have greater than 50 percent of new cancer patient population from minority ethnic groups. MBCCOPs will be required to enter patients onto NCI-approved treatment and cancer prevention and control clinical trials through the research base(s) with which each MBCCOP is affiliated. MECHANISM OF SUPPORT Support of this program will be through the Cooperative Agreement (410) an assistance mechanism in which substantial NCI programmatic involvement with the recipient during performance of the planned activity is anticipated, to assist awardees in the planning, direction, and execution of the proposed project. The anticipated amount of the direct cost awards will range from $100,000 to $200,000. The total project period for applications submitted in response to this RFA may not exceed three years for new applicants and four years for applicants currently supported under this program. Currently supported applicants will be funded for three or four years depending upon priority score/percentile, review committee recommendations, and program considerations. FUNDS AVAILABLE It is anticipated that up to $2.7 million in total costs per year for four years will be committed to specifically fund applications which are submitted in response to this RFA. It is anticipated that up to 12 MBCCOP awards will be made. This level of support is dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of NCI, awards pursuant to this RFA are contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES Background Overall, cancer incidence and mortality rates for many cancer sites in minority populations are higher compared to whites. Survival rates from cancer in minority populations are also less than in whites. One way to develop and implement effective cancer treatment, prevention and control strategies in minority populations, and thereby reduce disparities in cancer incidence, morbidity, and survival rates between whites and minority populations, is to provide broader access to benefits of clinical research and greater involvement of minority populations in the clinical trials process. NCI's clinical trials network has evolved over the past 30 years. The major NCI program initiatives supporting this network are the Clinical Cooperative Group Program, the Cancer Centers Program, the Cooperative Group Outreach Program, and the Community Clinical Oncology Program (CCOP). Treatment and cancer prevention and control clinical trials research funded through these programs provides patients and their physicians with access to state-of-the-art cancer care management opportunities, and provides oncologists with a source of continuing education on innovations in cancer therapy, diagnostic techniques, and treatment applications. The MBCCOP is an extension of the clinical trials network with the intent of including populations that have traditionally been unable to access the advantages of state of the art cancer care. Goals and Scope The MBCCOP, while designed to increase accrual of minority patients to clinical trials is also an opportunity to identify barriers to minority participation in clinical research and to test intervention strategies in cancer treatment, prevention and control. STUDY POPULATIONS SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES For projects involving clinical research, NIH requires applicants to give special attention to the inclusion of women and minorities in study populations. If women or minorities are not included in the study populations for clinical studies, a specific justification for this exclusion must be provided. Applications without such documentation will not be accepted for review. LETTER OF INTENT Prospective applicants are asked to submit, by June 25, 1993, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NCI staff to estimate the potential review workload and to avoid possible conflict of interest in the review. Letters of intent are to be sent to Dr. Otis W. Brawley, at the address listed under INQUIRIES. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for cooperative agreements. These forms are available at most institutional offices of sponsored research; from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone 301/594-7248; and from the NCI program official listed under INQUIRIES. A suggested format will be sent to all applicants requesting the RFA or submitting a letter of intent. Applicants are strongly encouraged to use the suggested format instructions for completing the PHS 398. Submit a signed, typewritten original of the application, including the Checklist, and three signed, exact, clear and single sided photocopies, in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, two additional copies of the application must also be sent to: Ms. Toby Friedberg Review Logistics Branch National Cancer Institute Executive Plaza North, Room 636 6130 Executive Boulevard Rockville, MD 20852 Applications must be received by August 24, 1993. If an application is received after that date, it will be returned to the applicant. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed by Division of Research ad Grants staff for completeness and NCI staff for responsiveness. Incomplete or non-responsive applications will be returned to the applicant without further consideration. If the number of applications is large compared to the number of awards to be made, applications may receive a preliminary scientific peer review (triaged) to determine their relative competitiveness. The NCI will withdraw from further competition those applications judged to be non-competitive for award and notify the applicant Principal Investigator and institutional official. Those applications judged to be competitive will undergo further scientific merit review in accordance with the criteria stated below for scientific/technical merit by an appropriate peer review group convened by the Division of Extramural Activities, NCI. The second level of review will be provided by the National Cancer Advisory Board. Review Criteria Review Criteria for MBCCOP applicants include the ability to accrue a minimum of 50 credits per year to cancer treatment clinical trials and a minimum of 30 credits in the first year of funding, 40 credits in the second year, and 50 credits in the third and fourth years to cancer prevention and control clinical trials. For MBCCOPs qualifications and experience of personnel and the stability and past performances of the functional unit applying will also be considered. The review group will critically examine submitted budgets and recommend an appropriate budget and period of support. AWARD CRITERIA The anticipated date of award is June 1, 1994. NCI program staff will take into account demographic and geographic distribution of applicants in the final funding selection process to assure inclusion of minority and undeserved populations. Multiple MBCCOP applicants for funding who are competing for the same patient population will be considered, but all may not be awarded unless warranted by the population density. INQUIRIES Written and telephone requests for the RFA, inquiries concerning the objectives and scope of this RFA, or about whether or not specific proposed research are responsive are encouraged and may be directed to: Otis W. Brawley M.D. Community Oncology and Rehabilitation Branch National Cancer Institute Executive Plaza North, Room 300 Bethesda, MD 20892 Telephone: (301) 496-8541 Direct inquiries regarding fiscal matters to: Ms. Crystal Elliott Grants Administration Branch National Cancer Institute Executive Plaza South, Room 243 Bethesda, MD 20892 Telephone: (301) 496-7800, Ext. 19 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 13.399, Cancer Control. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410 as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$R5 END ************************************************************ $$R6 BEGIN NR-93-005 FULL-TEXT ************************************** SMALL GRANTS PROGRAM FOR NURSING AND BIOLOGY INTERFACE NIH Guide, Volume 22, Number 18, May 7, 1993 RFA AVAILABLE: NR-93-005 P.T. 34; K.W. 0785130, 1002000, 1002008 National Center for Nursing Research Letter of Intent Receipt Date: July 1, 1993 Application Receipt Date: September 22, 1993 THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION. POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACTS NAMED IN INQUIRES, BELOW. PURPOSE The Small Grants Program (R03) will provide limited support for meritorious research that develops and tests innovative biological or molecular techniques for solving nursing problems or answering nursing clinical questions. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Small Grants Program for Nursing and Biology Interface, is related to the priority areas of physical activity, nutrition, and chronic disabling conditions. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00473-1) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS The research proposed must utilize state-of-the-science biotechnology and be an integral part of on-going research by a nurse scientist. The ongoing research must address a clinical issue relevant to the advancement of the practice of nursing. The applicant Principal Investigator must have a Ph.D. or the equivalent and an R.N. license. If the applicant PI is not actively involved in a biological science or molecular biology laboratory, collaboration with a biological or molecular biology scientist is required. The purpose of these requirements is to increase the numbers of beginning, mid-career and senior nurse researchers using state-of-the-science biological and molecular biology technology to answer clinical nursing questions. Nurse scientists funded with Fiscal Year 1993 monies in response to RFA: NR-92-04 are ineligible. Applications may be submitted by domestic for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Applications from women and minority individuals are encouraged. MECHANISM OF SUPPORT This RFA will use the National Institute of Health's (NIH) Small Grants (R03) Program mechanism. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. Awards will be administered under PHS grants policy as stated in the Public Health Service Grants Policy Statement (October 1, 1990). Each grant is limited to $50,000 in total costs for the entire project period. The Small Grants Program is a nonrenewable award. FUNDS AVAILABLE Approximately $200,000 in total costs will be committed to specifically fund applications submitted in response to this RFA. It is anticipated that four applications will be funded up to two years. This level of support is dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NCNR, awards pursuant to this RFA are contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES This RFA has two distinct aims: (1) To stimulate nurse investigators to explore innovative, state-of-the-science research using biological or molecular technology in order to answer clinical questions and nursing problems, and (2) To facilitate use of state-of-the-science biomolecular techniques by nurse researchers. The validation of nursing practice by the application of biological sciences and molecular biology into nursing research requires investigators to have the ability to use new techniques of structural and integrative biology, genetics, biophysics, and immunology. Example of Appropriate Biotechnology and Research Topics Biotechnology: recombinant DNA, gene mapping and/or sequencing, signal transduction, crystallographic analysis, peptide/protein modeling and molecular dynamics simulation, in vitro or in vivo nuclear magnetic resonance spectroscopy or imaging, positron emission tomography, isotopic scanning, monoclonal antibodies, high pressure liquid/gas chromatography, and spectrophotometry. Topics o A nurse scientist who investigates interventions to treat pain might be interested in measuring gene expression in the dorsal root ganglia, the site that changes amounts of messenger RNA after tissue and nerve injury. o A nurse scientist who investigates interventions to treat and prevent lead poisoning in school age children, might be interested in identifying blood cell markers as an immunological component of the health assessment in this population. The biotechnology might include biological and biochemical cellular markers to identify lead poisoning. o A nurse scientist whose basic science research involves identifying homeostatic mechanisms for regulating calcium ion concentration in cardiac cells might choose to study ionic flux and control as mechanisms in the degenerative process of cell function. o A nurse scientist whose clinical research is symptom management of complications arising from type II diabetes and obesity might be interested in the biochemical characterization of insulin resistance seen in these disorders. The R03 application might propose a study, in collaboration with a molecular biologist, of insulin function at the molecular level. o A nurse scientist whose clinical research is the quality of life after organ transplantation might be interested in evaluating immunologic indices of patient outcomes after bone marrow transplants. The R03 application might propose as study, in collaboration with an immunologist, of monoclonal antibodies produced by hybridomas in bone marrow transplants. STUDY POPULATIONS SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES For projects involving clinical research, NIH requires applicants to give special attention to the inclusion of women and minorities in study populations. If women or minorities are not included in the study populations for clinical studies, a specific justification for this exclusion must be provided. Applications without such documentation will not be accepted for review. LETTER OF INTENT Prospective applicants are asked to submit, by July 1, 1993, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the PI, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NCNR staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to: Ethel B. Jackson, DDS Office of Scientific Review National Center for Nursing Research Building 31, Room 5B19 Bethesda, MD 20892 Telephone: (301) 496-0472 FAX: (301) 480-4969 APPLICATION PROCEDURES The RFA contains important information for applicants and may be obtained from the contacts listed under INQUIRIES. The application receipt date is September 22, 1993. The research grant application form PHS 398 (rev. 9/91) is to be used. These forms are available at most institutional offices of sponsored research and the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone 301/594-7248. Applications must be submitted to the NIH Division of Research Grants. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed by NCNR staff for completeness and responsiveness. Incomplete applications will be returned to the applicant without further consideration. Those applications that are complete and responsive will be evaluated in accordance with stated criteria for scientific/technical merit by an appropriate special review group organized by NCNR. The second level of review will be provided by the National Advisory Council for Nursing Research. INQUIRIES Written and telephone requests for the RFA and the opportunity to clarify any issues or questions from potential applicants are welcome. Direct inquiries regarding programmatic issues to: Hilary D. Sigmon, Ph.D., R.N. Acute and Chronic Illness Branch National Center for Nursing Research Westwood Building, Room 754 Bethesda, MD 20892 Telephone: (301) 594-7397 FAX: (301) 594-7603 Direct inquiries regarding fiscal matters to: Sally A. Nichols Grants Management Officer National Center for Nursing Research Westwood Building, Room 748 Bethesda, MD 20892 Telephone: (301) 594-7498 FAX: (301) 594-7603 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.361, Nursing Research. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$R6 END ************************************************************ $$R7 BEGIN DK-93-007 FULL-TEXT ************************************** NON-INSULIN DEPENDENT DIABETES PRIMARY PREVENTION TRIAL NIH Guide, Volume 22, Number 18, May 7, 1993 RFA AVAILABLE: DK-93-007 P.T. 34; K.W. 0715075, 0755015, 0745027 National Institute of Diabetes and Digestive and Kidney Diseases National Institute of Child Health and Human Development Office of Research on Minority Health Letter of Intent Receipt Date: September 17, 1993 Application Receipt Date: October 19, 1993 THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION. POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES, BELOW. PURPOSE The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Child Health and Human Development (NICHD), and the Office for Research on Minority Health (ORMH) invite cooperative agreement applications for investigators to design and implement a full-scale, multicenter, randomized clinical trial to evaluate the efficacy of interventions designed to delay or prevent onset of non-insulin dependent diabetes mellitus (NIDDM) in individuals at increased risk for NIDDM. Within the broad range of this NIDDK and NICHD-sponsored initiative, ORMH is providing specific support for research focussing on the sub-population of obese minority women with a history of gestational diabetes. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, NIDDM Primary Prevention Trial, is related to the priority area of diabetes and chronic disabling conditions. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock Number 017-001-00474-0 or Summary Report: Stock Number 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone 202/783-3238. ELIGIBILITY REQUIREMENTS Applications may be submitted by for-profit and non-profit domestic organizations public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Minority individuals and women are encouraged to submit as Principal Investigators. Applications from minority institutions are especially encouraged. Applications from foreign institutions will not be considered. The expertise appropriate for this research program includes a knowledge of the clinical and epidemiological aspects of diabetes. Institutions wishing to collaborate and function as a single Clinical Center are required to submit one application. In this regard applicants are encouraged to form collaborative arrangements with investigators at minority institutions and/or minority investigators at other institutions. However international collaborations are unacceptable. MECHANISM OF SUPPORT The administrative and funding mechanism will be the cooperative agreement (U01). The cooperative agreement is an award instrument establishing an assistance relationship between the NIH and the recipients in which substantial programmatic involvement is anticipated between NIH and the recipients during performance of the contemplated activity. FUNDS AVAILABLE Support during the planning phase (Phase 1) of this trial for FY 1994 is expected to be approximately seven million dollars with total costs per center of approximately $350,000. It is anticipated that awards for 15 to 20 Clinical Centers will be made. During Phase 2 (full scale trial period) it is expected that funding levels for each center will increase to approximately $500,000 reflecting the start of the full scale trial. During Phase 3 (close-out period) costs are expected to decrease to approximately $100,000 in keeping with the reduction in clinical personnel effort and the shift to close-out, analysis of data, and reporting. Costs for outcome measures should not be included individually for each center. These costs will be covered under the Data Coordinating Center funding. From owner-sci-resources@net.bio.net Thu May 06 23:00:00 1993 Path: biosci!NET.BIO.NET!kristoff From: kristoff@NET.BIO.NET (Dave Kristofferson) Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 22, no. 18, pt. 2, 7 May 1993 Message-ID: Date: 7 May 93 18:16:53 GMT Sender: kristoff@net.bio.net Distribution: bionet Lines: 1247 $$XID NIHGUIDE 19930507 V22N18 P2O2 ************************************ Although this program is provided for in the financial plans of the NIDDK, the award of grants in response to the RFA is contingent on the availability of funds for this purpose. The total project period for applications submitted in response to the present RFA will be seven years due, in part, to the necessity to screen large numbers of potential participants to identify individuals with sufficient risk to answer the study question discussed under "RESEARCH OBJECTIVES". The anticipated award date is July 1994. RESEARCH OBJECTIVES The purpose of this RFA is to initiate a collaborative study of interventions to prevent NIDDM in people with IGT or a history of GDM and to prevent the worsening of glucose tolerance in people with newly diagnosed NIDDM. The study will determine whether onset of NIDDM can be delayed and whether interventions in newly diagnosed NIDDM can favorably influence glucose tolerance and progression to fasting hyperglycemia. STUDY POPULATIONS SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES For projects involving clinical research, NIH requires applicants to give special attention to the inclusion of women and minorities in study populations. If women or minorities are not included in the study populations for clinical studies, a specific justification for this exclusion must be provided. Applications without such documentation will not be accepted for review. LETTER OF INTENT Prospective applicants are asked to submit, by September 17, 1993, a letter of intent that includes the title of the proposed research, the name, telephone number and mailing address of the Principal Investigator, the identities of other key personnel and participating institutions, and the name of the applicant institution, and the number and title of this RFA. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information it contains is helpful in planning for the review of applications. It allows NIDDK staff to estimate the potential review workload and to avoid possible conflicts of interest in the review. The letter of intent is to be sent to: Robert D. Hammond, Ph.D. Division of Extramural Activities National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 605 Bethesda, MD 20892 Telephone: (301) 594-7515 FAX: (301) 594-7503 APPLICATION PROCEDURES Submit applications on form PHS 398 (rev. 9/91), the application form for NIH research project grant. This form is available in the applicant institution's office of sponsored research and may be obtained from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone (301) 594-7250. Applications must be received by October 19, 1993. An application not received by this date will be returned to the applicant. INQUIRIES Requests for copies of the RFA and inquiries regarding programmatic issues related to this announcement may be directed to: Sanford Garfield, Ph.D. Division of Diabetes, Endocrinology, and Metabolic Diseases National Institute of diabetes and Digestive and Kidney Diseases Westwood Building, Room 626 Bethesda, MD 20892 Telephone: (301) 594-7535 FAX: (301) 594-9011 Inquiries regarding fiscal matters may be directed to: Linda Stecklein Division of Extramural Activities National Institute of diabetes and Digestive and Kidney Diseases Westwood Building, Room 649B Bethesda, MD 20892 Telephone: (301) 594-7543 FAX: (301) 594-7594 Schedule Letter of Intent Receipt Date: September 17, 1993 Application Receipt Date: October 19, 1993 Initial Review: February/March 1994 Review by the NIDDK Council: May/June 1994 Anticipated Award Date: July 1994 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.847. Awards are made under the authority of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS Grants Policies and Federal Regulations 42 CFR Part 52 and 45 CFR parts 74 and 92. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$R7 END ************************************************************ $$R8 BEGIN DK-93-008 FULL-TEXT ************************************** NIDDM PRIMARY PREVENTION TRIAL: DATA COORDINATING CENTER NIH Guide, Volume 22, Number 18, May 7, 1993 RFA AVAILABLE: DK-93-008 P.T. 34; K.W. 0755015, 0745027, 0755018 National Institute of Diabetes and Digestive and Kidney Diseases Letter of Intent Receipt Date: September 17, 1993 Application Receipt Date: October 19, 1993 THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION. POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES, BELOW. PURPOSE The Division of Diabetes, Endocrinology and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites cooperative agreement applications for the Data Coordinating Center in a multicenter, randomized clinical trial to evaluate the efficacy of interventions designed to delay or prevent onset of non-insulin dependent diabetes mellitus (NIDDM) in individuals at increased risk for NIDDM. The Data Coordinating Center will participate with the NIDDK and fifteen to twenty Clinical Centers in all phases of this trial. A separate request for the Clinical Centers has been issued (RFA DK-93-007). The Data Coordinating Center and a participating Clinical Center may be located in the same institution; however, each must be administratively and fiscally distinct from the other. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, NIDDM Primary Prevention Trial, is related to the priority area of diabetes and chronic disabling diseases. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock Number 017-001-00474-0 or Summary Report: Stock Number 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone 202/783-3238. ELIGIBILITY REQUIREMENTS Applications may be submitted by for-profit and non-profit domestic organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Minority individuals and women are encouraged to submit as Principal Investigators. Applications from minority institutions are especially encouraged. Applications from foreign institutions will not be considered. The expertise appropriate for this research program includes statistical knowledge of the clinical and epidemiological aspects of diabetes and expertise in data coordination for clinical trials. MECHANISM OF SUPPORT The administrative and funding mechanism will be the cooperative agreement (U01). The cooperative agreement is an award instrument establishing an assistance relationship between the NIH and the recipients in which substantial programmatic involvement is anticipated between NIH and the recipients during performance of the contemplated activity. FUNDS AVAILABLE Support for the Data Coordinating Center during the planning phase (Phase 1) of this trial in FY 94 is expected to be approximately $1,000,000 (direct and indirect costs). During Phase 2 and 3 it is expected that the funding level for the Coordinating Center's direct operations will remain at this level corrected for inflation. However, funding will be provided by the NIDDK to support the Data Coordinating Center recruited and managed subcontracts for centralized laboratory and clinical resources reflecting the start of the full scale trial. Funds for the subcontract will be approximately five million dollars (total costs) during Phase 2 to support adherence and end point analyses. Additional funds in the first year of Phase 2 will be provided to cover the costs of screening. The nature and extent of the screening will be established by the outcome of the protocol development. Funds to support the subcontract aspects of the Trial will largely cease during Phase 3 reflecting the final period of data analysis and reporting. Although this program is provided for in the financial plans of the NIDDK, an award in response to the RFA is contingent on the availability of funds for this purpose. The total project period for applications submitted in response to the present RFA will be seven years due, in part, to the necessity to screen large numbers of potential participants to identify individuals with sufficient risk to answer the study question discussed under RESEARCH OBJECTIVES. The anticipated award date is July 1994. RESEARCH OBJECTIVES The purpose of this RFA is to initiate a collaborative study of interventions to prevent NIDDM in people with IGT and to prevent the worsening of glucose tolerance in people with newly diagnosed NIDDM. The study will determine whether onset of NIDDM can be delayed and whether interventions in newly diagnosed NIDDM can favorably influence glucose tolerance and progression to fasting hyperglycemia. The objectives of this RFA are to select a Data Coordinating Center to participate in a full-scale trial with the Clinical Centers and the NIDDK. STUDY POPULATIONS SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES For projects involving clinical research, NIH requires applicants to give special attention to the inclusion of women and minorities in study populations. If women or minorities are not included in the study populations for clinical studies, a specific justification for this exclusion must be provided. Applications without such documentation will not be accepted for review. LETTER OF INTENT Prospective applicants are asked to submit, by September 17, 1993, a letter of intent that includes a descriptive title of the proposed research, the name, address and telephone number of the Principal Investigator, the identities of other key personnel, and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent application, the information that it contains is helpful in planning for the review of application. It allows ICD staff to estimate the potential review workload and to avoid possible conflict of interest in the review. The letter of intent is to be sent to: Robert D. Hammond, Ph.D. Division of Extramural Activities National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 605 Bethesda, MD 20892 Telephone: (301) 594-7515 FAX: (301) 594-7503 APPLICATION PROCEDURES Submit applications on form PHS 398 (rev, 9/91), the application form for NIH research project grants. This form is available in the applicant institution's office of sponsored research and may be obtained from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone (301) 594-7250. INQUIRIES Requests for copies of the RFA and inquiries regarding programmatic issues related to this announcement may be directed to: Sanford Garfield, Ph.D. Division of Diabetes, Endocrinology, and Metabolic Diseases National Institute of diabetes and Digestive and Kidney Diseases Westwood Building, Room 626 Bethesda, MD 20892 Telephone: (301) 594-7535 FAX: (301) 594-9011 Inquiries regarding fiscal matters may be directed to: Linda Stecklein Division of Extramural Activities National Institute of diabetes and Digestive and Kidney Diseases Westwood Building, Room 649B Bethesda, MD 20892 Telephone: (301) 594-7543 FAX: (301) 594-7594 SCHEDULE Letter of Intent Receipt Date: September 17, 1993 Application Receipt Date: October 19, 1993 Initial Review: February/March 1994 Review by the NIDDK Council: May/June 1994 Anticipated Award Date: July 1994 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.847. Awards are made under the authority of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99- 158, 42 USC 241 and 285) and administered under PHS Grants Policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74 and 92. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$R8 END ************************************************************ $$XID RFA NR93005 NR-93-005 P1O1 *************************************** SMALL GRANTS PROGRAM FOR NURSING AND BIOLOGY INTERFACE NIH Guide, Volume 22, Number 18, May 7, 1993 RFA: NR-93-005 P.T. 34; K.W. 0785130, 1002000, 1002008 National Center for Nursing Research Letter of Intent Receipt Date: July 1, 1993 Application Receipt Date: September 22, 1993 PURPOSE The National Center for Nursing Research (NCNR) invites applications to develop or test innovative biological and molecular biological techniques for solving nursing problems and answering nursing clinical questions. This small grants program will provide limited support for meritorious research. The goal of this Request for Applications (RFA) is to generate significant findings so that nurse scientists can launch into investigator-initiated nursing research using biological or molecular technology. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Small Grants Program for Nursing and Biology Interface, is related to the priority area of physical activity, nutrition, and chronic disabling conditions. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00473-1) or"Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS The research proposed must utilize state-of-the-science biotechnology and be an integral part of on-going research by a nurse scientist. The ongoing research must address a clinical issue relevant to the advancement of the practice of nursing. The applicant Principal Investigator must have a Ph.D., or the equivalent, and an R.N. license. If the applicant Principal Investigator is not actively involved in a biological science or molecular biology laboratory, collaboration with a biological or molecular biology scientist is required. The purpose of these requirements is to increase the number of beginning, mid-career, and senior nurse researchers using state-of-the-science biological and molecular technology to answer clinical nursing questions. Nurse scientists funded with Fiscal Year 1993 monies in response to RFA NR-92-004 are ineligible. Applications may be submitted by domestic for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Applications from women and minority individuals are encouraged. MECHANISM OF SUPPORT This RFA will use the National Institute of Health (NIH) small grants (R03) Program mechanism. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. Awards will be administered under PHS grants policy as stated in the Public Health Service Grants Policy Statement (October 1, 1990). FUNDS AVAILABLE Approximately $200,000 in total costs will be committed to specifically fund applications submitted in response to this RFA. It is anticipated that four applications will be funded for up to two years. Each grant is limited to $50,000 in total costs for the entire project period. The Small Grants Program is a non-renewable award. This level of support is dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NCNR, awards pursuant to this RFA are contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES Background An important focus of nursing research in the improvement of patient care is the interaction of biological/molecular factors associated with acute and chronic illness, health promotion, and disease prevention. This small grants program is designed to assist the integration of advanced biological/molecular technology into nursing research and clinical practice. Recognizing the rapid changes that are taking place in the biological and molecular sciences and the effect these changes will have on nursing research and practice, the biological content of NCNR's portfolio was analyzed. A Nursing Biological Task Force recommended strategies to integrate nursing research with state-of-the-art biological science. These recommendations were approved by the National Advisory Council for Nursing Research (NACNR). A long-range plan for implementing the Task Force's recommendations includes research, career development, and training initiatives to increase the interface of biological sciences and molecular biology with nursing research as a basis for clinical practice. The first step of this plan was to increase opportunities for research training and career development in the biological sciences (PA-92-35, Training & Development: Nursing and Biology Interface). The second step of this plan targets research initiatives and its purpose is three-fold: (1) to facilitate the use of innovative biological and molecular biology technology in nursing research; (2) to link the biological and molecular underpinnings of nursing research and clinical practice in specified areas of biomolecular clinical research; and (3) to interweave nursing research and behavioral research with new areas of biomolecular science, such as structural and molecular biology, genetics, and immunology. Subsequent to the announcement of RFA NR-92-04, Small Grants Program for Nursing and Biology Interface, the Molecular Biology Nursing Task Force convened to identify NCNR participation in the first objective of the trans-NIH Strategic Plan, Critical Science and Technology. Its components include molecular medicine, biotechnology, molecular immunology and vaccine development, structural biology, and cellular and integrative biology. Focusing on solving nursing problems and answering clinical questions by using biological and molecular science, task force members recommended NCNR participation in the Critical Science and Technology objective: cellular and integrative biology, molecular medicine (molecular biology), molecular immunology and vaccine development, and bioengineering. The Task Force and the NACNR supported the opportunities available through NCNR to increase training, career development, and research opportunities in the interface between molecular biology and nursing research. Targeted Aims This RFA has two distinct aims: 1. To stimulate nurse investigators to explore innovative, state-of-the-science biological or molecular technology in order to answer clinical questions and nursing problems. 2. To facilitate use of state-of-the-science biomolecular techniques by nurse researchers. The validation of nursing practice by the application of biological sciences and molecular biology to nursing research requires investigators to have the ability to use new techniques of structural and integrative biology, genetics, biophysics, and immunology. Example of Appropriate Biotechnology and Research Topics Examples of biotechnology and topics appropriate to the objectives of this solicitation include: Biotechnology: recombinant DNA, gene mapping and/or sequencing, signal transduction, crystallographic analysis, peptide/protein modeling and molecular dynamics simulation, in vitro or in vivo nuclear magnetic resonance spectroscopy or imaging, positron emission tomography, isotopic scanning, monoclonal antibodies, high pressure liquid/gas chromatography, and spectrophotometry. Topics: o A nurse scientist who investigates interventions to treat pain might be interested in measuring gene expression in the dorsal root ganglia, in which the amount of messenger RNA changes after tissue and nerve injury. o A nurse scientist who investigates interventions to treat and prevent lead poisoning in school age children might be interested in identifying blood cell markers as an immunological component of the health assessment in this population. The biotechnology might include biological and biochemical cellular markers to identify lead poisoning. o A nurse scientist whose basic science research involves identifying homeostatic mechanisms for regulating calcium ion concentration in cardiac cells might choose to study the control of ionic flux in the degeneration of cell function. o A nurse scientist whose clinical research is symptom management of complications arising from type II diabetes and obesity might be interested in the biochemical characterization of insulin resistance seen in these disorders. The R03 application might propose a study, in collaboration with a molecular biologist, of insulin function at the molecular level. o A nurse scientist whose clinical research is the quality of life after organ transplantation might be interested in evaluating immunologic indices of patient outcomes after bone marrow transplants. The R03 application might propose as study, in collaboration with an immunologist, of monoclonal antibodies produced by hybridomas in bone marrow transplants. Methodological Issues A wide spectrum of research designs and analyses are acceptable under this solicitation. In preparing the application, the nurse investigator must develop specific hypotheses or research questions that apply biological or molecular technology to clinical nursing research questions. STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS NIH policy is that applicants for NIH clinical research grants and cooperative agreements are required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis should be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population based studies, a clear compelling rationale should be provided. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues must be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information must be included in the form PHS 398 (rev. 9/91) in Sections 1-4 of the Research Plan AND summarized in Section 5, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans, including American Indians or Alaskan Natives, Asian/Pacific Islanders, Blacks, Hispanics). The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research is defined as human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of disease, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. If the required information is not contained within the application, the application will be returned. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies. LETTER OF INTENT Prospective applicants are asked to submit, by July 1, 1993, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NCNR staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to: Ethel B. Jackson, D.D.S. Office of Scientific Review National Center for Nursing Research Building 31, Room 5B25 Bethesda, MD 20892 Telephone: (301) 496-0472 FAX: (301) 480-4969 APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research and from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone 301-594-7248. The RFA label available in the PHS 398 application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2a of the face page of the application form and the YES box must be marked. The following supplemental instructions are given: 1. Background and Significance: The applicant must be explicit in describing the interface of the chosen biological or molecular technique with clinical nursing research questions. 2. Progress Report/Preliminary Studies: Since this award mechanism intends to fund innovative technology, preliminary data are not required. 3. Sections 1, 2, and 4 of the Research Plan (Specific Aims, Background and Significance, and Research Design and Methods) are limited to a total of 10 pages. 4. Do not submit an Appendix. Submit a signed, typewritten original of the application, including the Checklist, and three signed photocopies, in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, two additional copies of the application must also be sent to Dr. Ethel B. Jackson at the address listed under LETTER OF INTENT. If the applicant has an approved assurance covering the research, the applicant should provide it with the application. Certification of Institutional Review Board (IRB) approval is required, if humans are involved. These reviews and approvals should occur prior to submission of the application for award and the certifications should be submitted with the application. There is no 60 day grace period for RFAs. If humans will be subjects of the research at performance sites other than the applicant organization, the applicant must identify, in the application, the assurance status of each participant. Failure to provide required certifications in the application could result in delay of an award. Instructions regarding inclusion of human subjects are given on pages 22-23 and 25-28 of PHS 398 (rev. 9/91). Applications must be received by September 22, 1993. If an application is received after that date, it will be returned to the applicant. The Division of Research Grants (DRG) will not accept any application in response to this announcement that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed by NCNR staff for completeness and responsiveness. Incomplete applications will be returned to the applicant without further consideration. Applications may be triaged by an NCNR peer review group on the basis of relative competitiveness. The NIH will withdraw from further competition those applications judged to be non-competitive for award and notify the applicant Principal Investigator and institutional official. Those applications judged to be competitive will undergo further scientific merit review. Those applications that are complete and responsive will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate peer review group convened by the NCNR. The second level of review will be provided by the NACNR. Review criteria for this RFA are generally the same as those for unsolicited research grant applications. o scientific and technical significance and originality of proposed research; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o qualifications and research experience of the Principal Investigator and staff, particularly, but not exclusively, in the area of the proposed research; o availability of resources necessary to perform the research; o appropriateness of the proposed budget and duration in relation to the proposed research; o the potential impact of the biological/molecular technique on nursing research and its ability to strengthen a subsequent R01 application. AWARD CRITERIA The anticipated date of award is April 1994. Decisions to make awards are based on the scientific merit of the application reflected in the priority score, availability of funds within the NCNR for this purpose, and NCNR research program priorities. INQUIRIES Written and telephone inquiries concerning this RFA are encouraged and should be directed to the following individuals. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic and scientific issues to: Hilary D. Sigmon, Ph.D., R.N. Acute and Chronic Illness Branch National Center for Nursing Research Westwood Building, Room 754 Bethesda, MD 20892 Telephone: (301) 594-7397 FAX: (301) 594-7603 Direct inquiries regarding budgetary and administrative matters to: Sally A. Nichols Grants Management Officer National Center for Nursing Research Westwood Building, Room 748 Bethesda, MD 20892 Telephone: (301) 594-7498 FAX: (301) 594-7603 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.361, Nursing Research. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$XID RFA DK93023 DK-93-023 P1O1 *************************************** INTERVENTIONS IN DIABETES AMONG MINORITY POPULATIONS NIH Guide, Volume 22, Number 18, May 7, 1993 RFA: DK-93-023 P.T. 34, FF; K.W. 0715075, 0785035, 0745027 National Institute of Diabetes and Digestive and Kidney Diseases National Center for Nursing Research Letter of Intent Receipt Date: July 20, 1993 Application Receipt Date: August 20, 1993 PURPOSE This Request for Applications (RFA) invites new and experienced investigators to submit clinical research applications designed to develop and validate intervention approaches for the amelioration or prevention of diabetes mellitus and/or its complications among minority populations, including African, Asian, and Hispanic Americans, Native Hawaiians, and Pacific Islanders. This RFA is a follow-up to the RFA DK-91-09 "Research Planning Grant: Diabetes in Minority Populations." However, respondents to this RFA are not restricted to those having previously received a planning grant under the prior RFA. Applications are encouraged from any interested investigators regardless of their prior record of grant support. Although this RFA is designed to develop and validate interventions for preventing diabetes mellitus and/or its complications, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is announcing another RFA (DK-93-007) specifically for clinical centers to design and implement a full-scale, multi-center clinical trial to evaluate the efficacy of interventions designed to delay or prevent onset of NIDDM in individuals at increased risk for the disease. The present RFA focuses on the specific minority populations as indicated above. An earlier RFA (DK-92- 17) was designed for studies with Native Americans and Alaskan Natives. While studies involving these populations are not responsive to the present RFA, investigators interested in working with these groups are advised to submit applications through the normal NIH investigator-initiated review process. The NIDDK and the National Center for Nursing Research (NCNR) seek to encourage research on all minority populations. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Interventions in Diabetes Among Minority Populations, is specifically targeted at diabetes mellitus and its complications as a major public health problem. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone: 202/783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign non-profit and for-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of state and local governments and eligible agencies of the Federal government. Teams of applicants are encouraged that could include universities, public health departments, voluntary organizations, and health clinics. Among a team of applicants, one institution must be proposed as the lead organization to serve as the Grantee Institution and assume responsibility for the fiscal and programmatic conduct of the project. Other members of the team should be proposed based on individual consortium agreements (subcontracts) with those organizations. The grantee organization and any proposed consortium must have the staff and facilities required for the proposed program. Applications from minority individuals and women are encouraged. MECHANISM OF SUPPORT Support of this program will be through the NIH research project grant (R01) award. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. Awards will be administered under PHS grants policy as stated in the PHS Grants Policy Statement. This RFA is a one-time solicitation. Future unsolicited competing continuation applications will compete with all investigator-initiated applications and be reviewed according to the customary peer review procedures. The total requested project period for applications submitted in response to this RFA may not exceed five years. A maximum of three years can be requested for foreign awards. The earliest possible award date will be April 1, 1994. Applicants must limit their request to not more than $160,000 direct costs for the initial budget period. The average size of an award is expected to be approximately $190,000. FUNDS AVAILABLE For fiscal year 1994, $2.2 million will be committed to fund applications submitted in response to this RFA. The NIDDK and the NCNR plan to support approximately 10 to 12 applications submitted in response to this solicitation. However, this funding level is dependent upon the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NIDDK and the NCNR, the award of grants pursuant to this RFA is contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES Background Diabetes mellitus and its complications are major public health problems in the United States today. The National Institutes of Health has encouraged research into the cause, cure and prevention of diabetes and its related endocrine and metabolic disorders. The Report of the Secretary of Health and Human Services Task Force on Black and Minority Health (1) identified non-insulin dependent diabetes mellitus (NIDDM) and its complications as major public health problems in several minority populations. This task force cited diabetes as one of six health problems responsible for excess mortality among United States minority populations. The rate of diabetes rises with age and reaches 15 to 20 percent among those 65 years of age and older. Rates in men and women are virtually equal. Until 1940, diabetes was less common in the African American population than in the general population. Today, the prevalence of NIDDM is 60 percent higher in African Americans than in the caucasian population. Diabetes is the fourth leading cause of death from disease in African American women and the seventh leading cause in African American men. Hispanic-Americans also suffer from diabetes to a degree disproportionate to their representation in the United States population as a whole. In the United States, approximately half of the people with NIDDM do not know they have the disease. Among African, Asian and Hispanic Americans, Native Hawaiians and Pacific Islanders, as in other populations, the symptoms of NIDDM can be very subtle and remain undetected for a long time. When diagnosed, NIDDM is usually treated with diet and exercise to control blood glucose levels. Oral hypoglycemic agents or insulin injections are employed if necessary. A variety of other interventions are also employed to help prevent or delay the chronic complications of diabetes that affect organs and tissues throughout the body. Obesity is a well-established risk factor for diabetes. For Hispanics, the rate of diabetes increases with each higher level of percent desirable weight (PDW). At obesity levels of PDW over 100, rates of diabetes are higher in the Hispanic population than in the African American population, and rates are higher in the African Americans than in the Caucasians. Most adults with diabetes in both Hispanic and African American populations are overweight, and women are particularly obese (20 percent or more above desirable weight). Obesity in children is a major concern. One in five American children is obese. Younger children weigh more and have more body fat than children the same age did 20 years ago. While the role of genes in predisposing people to diabetes is important, almost all obesity studies have found family influences are significant. The NIDDK sponsored two National Conferences in 1988 and 1989 to examine the problems of diabetes in African and Hispanic Americans and to define issues and priority areas for programs to reduce the impact of diabetes on these populations (2,3). During fiscal year 1992, NIDDK awarded Collaborative Research Planning Grants to support the development of collaborative research projects that address critical questions related specifically to the etiology, pathogenesis, diagnosis, treatment, cure and prevention of diabetes mellitus and its complications in African, Asian and Hispanic Americans, Native Hawaiians and Pacific Islanders. Scope The overall objective of this RFA is to stimulate original and innovative studies directed at the elucidation of practical methods for the reduction of the public health burden of diabetes in African, Asian and Hispanic Americans, Pacific Islanders, and Native Hawaiians. Applicants must demonstrate that their research teams have an understanding of and are sensitive to the target populations. Any proposed intervention must be culturally relevant and acceptable. Special consideration will be given to investigators with demonstrated access, knowledge, and cultural sensitivity to Native Hawaiians, Pacific Islanders and African, Asian and Hispanic Americans. Examples of research topics relevant to this solicitation are listed below, they should not be construed as required or limiting. Responsive applications to this RFA include: o Development and validation of efficacious strategies for changing health behaviors of people with or at high risk for diabetes, with specific emphasis on high risk populations. o Development and validation of interventions designed to prevent NIDDM or its major risk factors, such as obesity, on a community wide basis for high risk populations. o Development and validation of interventions designed to prevent NIDDM in targeted high risk subgroups (e.g., documented impaired glucose tolerance, history of gestational diabetes, obese children or young adults) within the population. o Development and validation of interventions designed to improve the care of minority patients with NIDDM. o Development and validation of interventions designed to reduce or prevent the long-term complications of diabetes among minority populations. o Clinical studies of the physiologic effects of alternative pharmacologic and non-pharmacologic interventions for the treatment of NIDDM in minority populations. SPECIAL REQUIREMENTS The research team, composed of the Principal Investigator and/or collaborators, must include individual(s) who are experienced in clinical research. Involvement of individuals who have demonstrated experience working with or delivering health services to minority populations is highly desirable. The application should include a succinct discussion of previous relevant investigational and health care activities. Letters of collaboration should be included for all proposed consultants/collaborators. The applicant must demonstrate that the research team has an understanding of and sensitivity to the target population. Where specific language or cultural barriers are important, the applicant must provide a plan for addressing these barriers. STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF MINORITIES AND WOMEN IN CLINICAL RESEARCH STUDY POPULATIONS NIH policy is that applicants for NIH clinical research grants and cooperative agreements are required to include minorities and women in study populations so that research findings can be of benefit to all person at risk of the disease, disorder or condition under study; special emphasis must be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale must be provided. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues must be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information must be included in the form PHS 398 (rev. 9/91) in Item 4 (Research Design and Methods) of the Research Plan AND summarized in Item 5, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations; i.e., Native Americans [including American Indians or Alaskan Natives], Asian/Pacific Islanders, African Americans and Hispanics. The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research is defined as human biomedical behavioral studies or etiology, epidemiology, prevention [and preventive strategies], diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research or human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. For foreign awards, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign population groups to the United States' populations, including minorities. If the required information is not contained within the application, the application will be returned without review. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies. LETTER OF INTENT Prospective applicants are asked to submit a letter of intent by July 20, 1993. The letter of intent should include a descriptive title of the proposed research, the name and address of the Principal Investigator, the names of key personnel, the participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NIDDK staff to estimate the potential review workload and to avoid possible conflict of interest in the review. The letter of intent is to be sent to: Chief, Review Branch Division of Extramural Activities National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 605 Bethesda, MD 20892 Telephone: (301) 594-7515 APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. The form is available from most institutional offices of sponsored research and from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone (301) 594-7250. The RFA label available in the PHS 398 must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the title of the RFA and the number must be typed on line 2a of the face page on the application form and check the yes box. Submit a signed, original of the application, including the Checklist, and three signed, exact photocopies, in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At time of submission, two additional copies of the application must also be sent under separate cover to: Chief, Review Branch Division of Extramural Activities National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 605 Bethesda, MD 20892 Applications must be received by August 20, 1993. If an application is received after that date, it will be returned to the applicant. The Division of Research Grants (DRG) will not accept any application in response to this announcement that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. However, it is allowable to submit the same project as both an R01 and as a component project of a program project. The DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications previously reviewed. Such applications must not only include an introduction addressing the previous critique but also be responsive to this RFA. REVIEW CONSIDERATIONS Upon receipt, applications will be initially reviewed by the Division of Research Grants (DRG) for completeness. Incomplete applications will be returned to the applicant without further consideration. Evaluation for responsiveness to the program requirements and criteria stated in the RFA is an NIDDK staff function. If the application is not responsive to the RFA, NIDDK staff will contact the applicant to determine whether it should be returned to the applicant, or whether it should be held until the next regular receipt date and reviewed in competition with all other applications. Those applications that are complete and responsive will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate peer review group convened by the NIDDK. If the number of applications is large compared to the number of awards to be made, a preliminary scientific peer review may be conducted and applications withdrawn from further competition if they are not competitive for the award. The NIDDK will notify the applicant and institutional official of this action. Those applications judged to be competitive will be reviewed for scientific and technical merit in accordance with the usual NIH peer review procedures by an initial review group within the NIDDK specifically convened for this RFA. Following this review, the applications will be given a secondary review by the National Advisory Councils unless not recommended for further consideration by the initial review group. Review criteria for RFAs are generally the same as those for unsolicited research grant applications. o scientific/technical merit criteria specific to the objectives of the RFA; o scientific, technical, or medical significance and originality of proposed research; o appropriateness and adequacy of the experimental approach, methodology and staff, particularly but not exclusively in the area of the proposed research; o availability of resources necessary to perform the research; o appropriateness of the proposed budget and duration in relation to the proposed research; o if an application involves activities that could have an adverse effect upon humans, animals, or the environment, the adequacy of the proposed-means for protecting against or minimizing such effects; and o for foreign applications, the uniqueness of research such that it can only be performed outside of the United States. AWARD CRITERIA Applications will compete for available funds with all other recommended applications submitted in response to this RFA. The following will be considered in making funding decisions: o Quality of the proposed project as determined by peer review o Availability of funds o Program balance among research areas of the announcement. The anticipated date of award is April 1, 1994. INQUIRES Written and telephone inquiries concerning this RFA are encouraged. Inquires regarding programmatic issues may be directed to: Charles A. Wells, Ph.D. Division of Diabetes, Endocrinology, and Metabolic Diseases National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 622 Bethesda, MD 20892 Telephone: (301) 594-7505 June R. Lunney, Ph.D., R.N. Acute and Chronic Illness Branch National Center for Nursing Research Westwood Building, Room 754 Bethesda, MD 20892 Telephone: (301) 594-7397 Inquiries regarding fiscal matters may be directed to: Mrs. Betty Bailey Division of Extramural Activities National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 649 Bethesda, MD 20892 Telephone: (301) 594-7543 Sally A. Nichols Grants Management Officer National Center for Nursing Research Westwood Building, Room 748 Bethesda, MD 208932 Telephone: (301) 594-7498 Schedule Letter of Intent Receipt Date: July 20, 1993 Application Receipt Date: August 20, 1993 Initial Review: October/November 1993 Anticipated Date of Award: April 1, 1994 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No 93.848. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99- 158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. REFERENCES 1. United States Department of Health and Human Services. Report of the Secretary's Task Force on Black and Minority Health. Vol. VII, United States Government Printing Office, Washington, D.C., January 1986. 2. Proceeding of the Symposium on Diabetes in African Americans: Diabetes Care, Volume 13, No. 11, Supplement 4, November 1990. 3. Proceeding of the Symposium on Diabetes in Blacks: Diabetes Care, Volume 14, No. 17, Supplement 3, July 1991. From owner-sci-resources@net.bio.net Thu May 06 23:00:00 1993 Path: biosci!kristoff From: kristoff@net.bio.net (David Kristofferson) Newsgroups: bionet.sci-resources Subject: This newsgroup is now moderated Message-ID: Date: 7 May 93 23:39:18 GMT Organization: BIOSCI International Newsgroups for Biology Lines: 16 Approved: biosci-moderator@net.bio.net This newsgroup i